Decompensated NASH Cirrhosis Research Study

IRB/UVA Tracking #
20302
Principal Investigator
Caldwell Stephen, H
Contact First Name

Jennifer

Contact Last Name

Greene

Contact Email
Contact Phone
Official Trial Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Study Description

The GI Hepatology Department is seeking participants ages 18 and older with NASH cirrhosis who have had ascites or a GI bleeding event for a research study. The purpose of the study is safety and efficacy of an experimental drug for at least 48 weeks.

Study involves taking an experimental medicine or placebo, blood draws, MRIs, ultrasounds, and other non-invasive testing. There will be at least 15 visits every 4 weeks, each visit lasting 1-3 hours.

Study-related insert exams, tests and experimental medication are all provided free of charge. Reimbursement for mileage may be available for travel greater than 50 miles from UVA.

Compensation

$75/visit